HIV Infections
Conditions
Keywords
Anti-HIV Agents, Viral Load, dextrin 2-sulfate, Infusions, Parenteral
Brief summary
The purpose of this study is to look at the safety and effectiveness of dextrin sulfate in AIDS patients who have failed conventional anti-HIV treatment.
Detailed description
Patients have intraperitoneal (IP) catheter placement done at study entry. Infusion with the carrier vehicle (icodextrin 4%) begins 2 weeks later, and 2 days after that, treatment with dextrin sulphate (DS) commences. DS is given three times per week. A nurse delivers initial treatments and the patient and caregiver will be trained to give subsequent treatments until DS has been given a total of 8 weeks. Patient evaluations are done regularly during treatment and observation continues for 24 weeks.
Interventions
DRUGDextrin 2-sulfate
Sponsors
Steinhart Medical Associates
Study design
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients may be eligible for this trial if they: * Are HIV-positive. * Have been diagnosed with AIDS and are under treatment to prevent opportunistic (AIDS-related) infection. * Have had a CD4 cell count greater than 50 microL for at least the past 3 months. * Have had a viral load of at least 50,000 copies/ml for at least the past 3 months. * Have used up all other treatment options. * Are able to understand and give written consent.
Exclusion criteria
Patients may not be eligible for this trial if they: * Have been in any other study in the 6 weeks before beginning this study. * Have an active, opportunistic infection or other infection. * Have any other long-term medical condition or nervous disorder that might make it difficult for them to finish the study.
Countries
United States
Outcome results
None listed